Husseini Manji, MD, FRCPC is Co-chair of the UK Govt Mental Health Mission, Professor, Oxford University, Visiting Professor, Duke University, and past Global Head for Neuroscience at J&J. He was previously Chief of NIH Laboratory of Molecular Pathophysiology, and Director of NIH Mood and Anxiety Disorders Program, the largest program of its kind in the world. He has been inducted into the National Academy of Medicine (NAM), is a member of the NIH Novel/Exceptional Technology and Research Advisory Committee, the World Dementia Council, is co-chair of the Board of the Healthy Brains Global Initiative, is recent chair of NAM Neuroscience, Behavior, Brain Function group, and has held numerous leadership positions within the NIH, NAM, the FNIH Biomarkers Consortium Executive Committee. Dr. Manji has helped to discover/develop/launch several new medications for serious neuropsychiatric/neurodegenerative disorders, including the first novel antidepressant mechanism in over 30 years, the first-ever Neuroscience medication to be granted US FDA “breakthrough therapy” designation and novel treatments for schizophrenia, and Alzheimer’s disease, others. He has received numerous International awards, including NIMH Director's Career Award for Significant Scientific Achievement, the National Academy of Medicine International Mental Health Prize, PhRMA Excellence in Research Award, A. E. Bennett & Ziskind-Somerfeld Awards for Neuropsychiatric Research, several distinguished research awards and > 350 peer-reviewed publications.